Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.51 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
| ▸ | TK2 | O00142 | 12/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315534 | 1.00 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL5888977 | 1.00 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL31723482 | 1.00 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL5502782 | 0.94 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL6850137 | 0.94 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL7068149 | 0.93 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL7068162 | 0.93 | TYMP (0.51) | TYMPTK1TK2 | |
| SCHEMBL30216573 | 0.92 | TYMP (0.47) | TYMPTK1TK2 | |
| SCHEMBL22984025 | 0.92 | TYMP (0.54) | TYMPTK1TK2 | |
| SCHEMBL7702801 | 0.92 | TYMP (0.54) | TYMPTK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | disclosed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2921499-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | POLM, POLRMT, RNMT | TYMP 123/4885TK1 99/4885TK2 303/4885 |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | TYMP 165/4885TK1 95/4885TK2 448/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | TYMP 257/4885TK1 104/4885TK2 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.